

1 **Molecular surveillance detects high prevalence of the neglected parasite *Mansonella***  
2 ***ozzardi* in the Colombian Amazon**

3 Dahmer KJ<sup>1</sup>, Palma-Cuero M<sup>1,2</sup>, Ciuoderis K<sup>2,3</sup>, Patiño C<sup>3</sup>, Roitman S<sup>4</sup>, Li Z<sup>4</sup>, Sinha A<sup>4</sup>, Hite JL<sup>1</sup>,  
4 Bellido Cuellar O<sup>5</sup>, Hernandez-Ortiz JP<sup>2,3</sup>, Osorio JE<sup>1,2</sup>, Christensen BM<sup>1,2</sup>, Carlow CKS<sup>4</sup>,  
5 Zamanian M<sup>1,2\*</sup>

6 <sup>1</sup> Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, WI USA

7 <sup>2</sup> University of Wisconsin Global Health Institute One Health Colombia, Madison, WI USA

8 <sup>3</sup> Universidad Nacional de Colombia - UW-GHI One Health Colombia, Medellín, Colombia

9 <sup>4</sup> New England Biolabs, 240 County Road, Ipswich, MA USA

10 <sup>5</sup> Secretaría de Salud Departamental del Amazonas, Leticia, Colombia

11

12 Correspondence: \*[mzamanian@wisc.edu](mailto:mzamanian@wisc.edu)

13 **Abstract**

14 Mansonellosis is an undermapped insect-transmitted disease caused by filarial nematodes that  
15 are estimated to infect hundreds of millions of people globally. Despite their prevalence, there  
16 are many outstanding questions regarding the general biology and health impacts of the  
17 responsible parasites. Historical reports suggest that the Colombian Amazon is endemic for  
18 mansonellosis and may serve as an ideal location to pursue these questions in the backdrop of  
19 other endemic and emerging pathogens. We deployed molecular and classical diagnostic  
20 approaches to survey *Mansonella* prevalence among adults belonging to indigenous  
21 communities along the Amazon River and its tributaries near Leticia, Colombia. Deployment of a  
22 loop-mediated isothermal amplification (LAMP) assay on blood samples revealed an infection  
23 prevalence of ~40% for *Mansonella ozzardi*. This assay identified significantly more infections  
24 than blood smear microscopy or LAMP assays performed using plasma, likely reflecting greater  
25 sensitivity and the ability to detect low microfilaremias or occult infections. *Mansonella* infection  
26 rates increased with age and were higher among males compared to females. Genomic  
27 analysis confirmed the presence of *M. ozzardi* that clusters closely with strains sequenced in  
28 neighboring countries. We successfully cryopreserved and revitalized *M. ozzardi* microfilariae,  
29 advancing the prospects of rearing infective larvae in controlled settings. These data suggest an  
30 underestimation of true mansonellosis prevalence, and we expect that these methods will help  
31 facilitate the study of mansonellosis in endemic and laboratory settings.

32

33 **Keywords:** *Mansonella ozzardi*, epidemiology, loop-mediated isothermal amplification,  
34 diagnostics, genomics, cryopreservation

35 **Topic:** Colombia, Amazonia, *Mansonella*, infection, infectious disease, *Culicoides*

36 **Section:** Parasitology

37

38

39

## 40 Introduction

41 Mansonellosis is a highly prevalent but undermapped [1] and understudied parasitic disease  
42 that infects hundreds of millions of people throughout Africa and Central and South America [2].  
43 Three species of insect-transmitted parasitic nematodes (*Mansonella ozzardi*, *M. perstans* and  
44 *M. streptocerca*) are responsible for the majority of human cases although other *Mansonella*  
45 species have the potential to infect humans, including the recently discovered *Mansonella* sp.  
46 “DEUX” which has revitalized demands for allocating resources to study this severely neglected  
47 disease [2–5].

48  
49 There are major gaps in our understanding of the basic biology and clinical or subclinical  
50 impacts of mansonellosis in human populations. *Mansonella* infections underlie variable clinical  
51 presentations that are likely underrecognized [4] and may alter host immunity in ways that alter  
52 vaccine responses and susceptibility to other pathogens [6–8]. Drugs used in mass drug  
53 administration campaigns for lymphatic filariasis and onchocerciasis are not as effective against  
54 *Mansonella* spp. [9–13] suggesting a unique genetic basis for anthelmintic resistance [14–16].  
55 Additionally, *Mansonella* infections can introduce diagnostic challenges related to species mis-  
56 identification [17,18], cross-reactivity of immunochromatographic tests [19,20], and the inability  
57 to easily discern occult or amicrofilaremic infections [21]. Together, these limitations can  
58 potentially confound parasite elimination and surveillance programs focused on more prominent  
59 filarial worm parasites in co-endemic regions [9–13,16].

60  
61 To address these challenges, we deployed both classical and molecular diagnostic approaches  
62 to carry out more precise epidemiological surveys of *Mansonella* prevalence in adults from  
63 villages along the Amazon River and its tributaries around the capital city of Leticia in the  
64 Amazonas Department of Colombia. The Amazon basin is historically associated with “new  
65 world” *M. ozzardi* [22–25] and is ideally situated to pursue fundamental questions about  
66 *Mansonella* biology, clinical presentations, and interactions with other pathogens that are  
67 endemic in the region. Parasite surveys in this region are outdated [22–24], but incidental  
68 findings from community health workers in the course of malaria screening and estimates from  
69 communities in neighboring countries [4,21,26] suggest a high prevalence.

70  
71 The gold standard diagnostic for *M. perstans* and *M. ozzardi* is blood smear microscopy, which  
72 requires morphological differentiation of the circulating microfilariae (mf) stage [4,17]. Molecular  
73 diagnostic approaches including real-time PCR (RT-PCR) [27–29] are largely restricted to  
74 laboratory settings. However, more recently developed loop-mediated isothermal amplification  
75 (LAMP) assays with a simple colorimetric readout are more amenable to field studies [30]. We  
76 comparatively profiled LAMP assays with classical microscopy-based techniques to evaluate  
77 potential underestimation of parasite prevalence among a cluster of indigenous communities in  
78 the Colombian Amazon region. Microfilariae were isolated for population genomic analyses of  
79 *Mansonella* with respect to previously characterized field isolates, as well as for the  
80 establishment of a cryopreservation protocol to enable laboratory studies. Lastly, we probed  
81 associations of *Mansonella* infection status with other clinical and demographic variables. We  
82 expect that these data and methods will help facilitate future studies of *Mansonella*.

## 83 Methods

### 84 Study design and sampling procedure

85 This study was conducted between 2021 and 2023 in the Amazonas Department of Colombia in  
86 areas surrounding the capital city of Leticia and Puerto Nariño municipalities (**Figure 1A**). This  
87 region of vast biodiversity is largely populated by indigenous communities situated near the  
88 Amazon River and its tributaries. The study protocol was reviewed and approved by the UW-  
89 Madison IRB (study # 2019-1107) and Corporación para Investigaciones Biológicas (CIB  
90 #17022021). The study population (n = 235) from 13 communities was recruited by convenience  
91 and individuals  $\geq 18$  years of age were invited to participate and enrolled after providing written  
92 informed consent. Peripheral (venous) blood samples were collected into  
93 ethylenediaminetetraacetic acid (EDTA) tubes and thin and thick blood smears were prepared  
94 and examined for the presence of filarial parasites and malaria. Serum/plasma were extracted  
95 and aliquoted along with whole blood into 1.5 mL tubes and stored at  $-80^{\circ}\text{C}$  for detection of  
96 *Mansonella* and other pathogens (**Figure 1B**). Self-reported socio-demographic and  
97 epidemiological data were collected using a structured questionnaire through face-to-face  
98 interviews at the enrollment site. Recorded data included demographics (age, sex, ethnicity,  
99 occupation, place of residence), housing conditions, travel history, medical history (pre-existing  
100 diseases), and clinical symptoms.

101

#### 102 **Figure 1**

103 **A)** Map of the study region in the Amazonas Department of Colombia depicting the capital city  
104 of Leticia and the Puerto Nariño municipality where samples were collected across three  
105 surveys. The study region is adjacent to the Amazon River at the borders of Colombia, Brazil,  
106 and Peru. **B)** Schematic of sampling efforts and endpoints for blood samples acquired from  
107 adult volunteers. Blood smears and preparations of cryopreserved samples were conducted in  
108 the field. Whole blood was obtained in EDTA tubes and transferred on ice to a laboratory in  
109 Leticia. Aliquots of whole-blood and plasma were prepared from samples and used for  
110 downstream serology, molecular diagnostics, and genomic analyses. Questionnaires were filled  
111 out at the time of sampling.

### 112 Microscopy smears and microfilariae quantification

113 Routine thin and thick smears were prepared at the time of blood draws. Slides were allowed to  
114 dry at room temperature, Giemsa stained and examined microscopically. For quantitative  
115 microscopy, 40  $\mu\text{L}$  of thawed blood was mixed with equal amounts of water and microfilaria (mf)  
116 were counted using light microscopy. For filtration of thawed blood aliquots, 1 mL of blood  
117 mixed with 4 mL of phosphate-buffered saline (PBS) was added to a Millipore syringe (Sigma-  
118 Aldrich, Z268429) with a 5  $\mu\text{m}$  filter membrane (Millipore Sigma, TMTP02500). Filter  
119 membranes were imprinted in a microscope slide, allowed to dry before methanol fixation and  
120 Giemsa staining for microscopical observation.

## 121 Cryopreservation and recovery of microfilariae

122 Blood samples were transported on ice from Puerto Nariño to Leticia, where they were mixed  
123 with 5% dimethyl sulfoxide (DMSO) at a 1:1 ratio, aliquoted in cryogenic tubes and stored at -  
124 80°C [31]. Processed samples were then shipped to Medellin and stored at -80°C. Samples  
125 were thawed in a water bath at 37°C for 5 minutes and washed twice with sterile PBS (at 37°C),  
126 followed by centrifugation at 2,000 rpm for 10 minutes. The mf pellet was gently mixed with 2  
127 mL of RPMI-1640 + 1x Antibiotic-Antimycotic (Gibco, 15240096). 1 mL aliquots were added to  
128 wells in a 6-well cell culture plate and the plate was incubated at 37°C and 5% CO<sub>2</sub>. Movement  
129 patterns of mf were recorded using an inverted microscope (40X objective). Movement levels  
130 were quantified using a customized optical flow pipeline[32].

## 131 DNA extraction from blood and plasma samples

132 DNA was extracted from whole blood and plasma using the Quick-DNA 96-plus kit (Zymo,  
133 D4070/71) with minor adjustments to the protocol. For blood samples, the “solid tissue protocol”  
134 was followed by adding 50 µL of blood in place of water and tissue. After incubation for 2.5  
135 hours, samples were spun at 3,500g for 2 minutes and supernatant lysate was transferred to the  
136 Zymo-spin 96-XL plate. For plasma samples, the “biological fluid and cells” protocol was  
137 followed. Final DNA was eluted with 15 µL of water and concentrations were assessed via  
138 NanoDrop for quality assurance.

## 139 Loop-mediated isothermal amplification assays

140 LAMP reactions were carried out as previously described [30] with slight modifications. Briefly,  
141 each LAMP reaction contained 1.6 µM each of primers FIP (5'-CGCAAACAGAAGCCCCGAAAC-  
142 GCTCGCAATTTTCATAGTGG-3') and BIP (5'-CTTGCGCGTAGCATTAGATCC-  
143 TCCGAAATGTATACGACAGAT-3'), 0.2 µM each of F3 (5'-GCACGAAATGTTTTTGTACG-3')  
144 and B3 (5'-CGTATCACCGTTGATGACG-3'), 0.4 µM each of LF (5'-  
145 AAGCCTAAGCCTAAGCCTGA-3') and LB (5'-GCACATCTTCAATCTCCTCTTGC-3'), 2 µl 10X  
146 GuHCL, 10 µl of WarmStart Colorimetric LAMP 2x Master Mix (NEB, M1804L), 4 µl water and 2  
147 µl of template DNA, or 2 µl water for non-template controls for a total volume of 20 µl per  
148 reaction. For a colorimetric readout, reactions were incubated at 63°C for 30 minutes in a  
149 SimpliAmp Thermocycler (Applied Biosystems, A24811) and images were acquired using an  
150 ImageQuant 800 (Cytiva). A post amplification color of yellow indicated detection of *M. ozzardi*,  
151 and pink (or orange) indicated no detection.

152  
153 For semi-quantitative LAMP (sq-LAMP), simultaneous colorimetric and fluorescent readouts  
154 were obtained by adding SYTO™ 9 green (Invitrogen, S34854) to a final concentration of 1 µM  
155 in the colorimetric LAMP reaction. Reactions were performed in a Bio-Rad CFX Opus 96 Real-  
156 Time PCR instrument at 65°C with total fluorescence read in the SYBR/FAM channel every 15  
157 seconds for 150 “cycles” (~53 minutes with each “cycle” corresponding to 21.2 seconds of  
158 reaction time, 15 seconds combined with plate reading time). A cut-off time threshold (Tt) value  
159 of 30 minutes was used to differentiate positive/negative reactions, with Tt defined as the time  
160 (min) to reach the fluorescence detection threshold. A Tt ≤ 30 minutes indicated the detection of

161 the target, whereas a Tt > 30 minutes or N/A, indicated no detection. Plates were scanned using  
162 the Epson Perfection v600 Photo Scanner.

## 163 DNA extraction and Illumina library construction and sequencing

164 DNA was extracted from 200  $\mu$ L of whole blood using the MagAttract HMW DNA kit (Qiagen,  
165 67563) following the manufacturer's instructions. The NEBNext Microbiome DNA enrichment kit  
166 (NEB, E2612) was used as directed to enrich *Mansonella* DNA and reduce human DNA prior to  
167 library construction. The Illumina libraries were constructed using the NEBNext Ultra II DNA  
168 Library Prep Kit for Illumina (NEB, E7645) as described by the manufacturer. The quality and  
169 concentration of each library were determined using a 2100 Bioanalyzer with a high-sensitivity  
170 DNA chip (Agilent Technologies). Libraries were diluted to 1  $\mu$ M with 10  $\mu$ M Tris, 0.1  $\mu$ M  
171 EDTA pH 8. Phi X DNA (5%) was added to balance base pair composition in these A:T rich  
172 filarial libraries prior to sequencing on a NovaSeq platform (paired end, 150  $\mu$ bps).

## 173 Bioinformatic analysis

174 Raw Illumina reads were processed to remove adapters and poor-quality reads using the  
175 BBTools package (<https://jgi.doe.gov/data-and-tools/bbtools/>). For each isolate, the reads were  
176 mapped to a combined reference sequence set comprising a *M. ozzardi* reference genome from  
177 Brazil [16], a reference mitogenome KX822021.1 [33] and the *Wolbachia* wMoz assembly  
178 GCF\_020278625.1 [34] using bowtie2 [35]. Reads mapping to mitochondria were extracted  
179 from the bam alignment files using samtools [36] and assembled into circular mitochondrial  
180 genomes using GetOrganelle v1.7.7.0 [37]. The average nucleotide identity scores between  
181 pairs of all assembled mitogenomes and published mitogenomes, namely the accessions  
182 KX822021.1 and MN416134.1 for *M. ozzardi* [21,33] and MT361687.1 and MN432521.1 for *M.*  
183 *perstans* [21,38] were calculated using the OrthoANIu tool [39]. Multiple sequence alignments of  
184 all *M. ozzardi* and *M. perstans* mitogenomes were obtained using mafft v7.149b [40]. The  
185 phylogenetic tree based on this alignment was generated using the iqtree online server [41],  
186 which performs automatic best fit substitution model selection using ModelFinder [42]. Bootstrap  
187 support values were calculated based on ultrafast bootstrap [43] with 1000 replicates. The tree  
188 was annotated on the iTOL webserver [44].

## 189 Serological tests for viral infections

190 Serum samples were used for antibody detection against several pathogens. Anti-dengue  
191 immunoglobulin G (IgG) and IgM were detected using SD BIOLINE Dengue Duo rapid test  
192 (Abbott), following manufacturer's instructions. Anti-Human Immunodeficiency Virus (HIV),  
193 Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) as well as anti-IgM against Severe Acute  
194 Respiratory Syndrome Coronavirus 2 (SARS-COV-2) were detected by chemiluminescence  
195 immunoassay using the Architect I1000 system (Abbott), following manufacturer's instructions.

## 196 Data analysis

197 Self-reported data were recorded on printed surveys by study personnel and completed forms  
198 were entered into Microsoft Excel by double entry. Excel spreadsheets were used for data  
199 inspection, cleaning, and quality control before data analysis using R Studio software v4.2.2  
200 (42). To examine sex- and age-based differences of *M. ozzardi* infections, we used a linear  
201 model (lm) to get the residuals and assess the normality of our data. We determined our data  
202 did not follow a normal distribution (Shapiro-Wilk test, male age:  $W = 0.93224$ , p-value =  
203  $0.0002649$ , female age:  $W = 0.89475$ , p-value =  $8.05e-09$ ). Based on these results, we ran a  
204 non-parametric Wilcoxon rank sum test with a p-value  $< 0.05$  considered statistically significant.  
205 Next, to examine differences between infection prevalence across demographic variables and  
206 analyses on reported symptoms and serology results, we used generalized linear models  
207 (GLMs) with binomial distributions and log link functions [45]. We conducted model selection  
208 analyses using the *aictab* function in the R package AICcmodavg [46]. We built candidate  
209 models starting with the full model with all combinations of main effects among relevant  
210 biological and methodological factors, while avoiding overfitting. We compared candidate  
211 models using Akaike's information criterion and  $\Delta AIC$  (the difference in AIC values for the focal  
212 model and the model with the lowest AIC, i.e., the 'winning' model) [47]. We also calculated the  
213 Akaike weight ( $w$ ), which further quantifies the probability that a model is the most appropriate  
214 model relative to the candidate models (**Supplementary Table 1**).  $\Delta AIC$  less than two and a  
215 higher  $w$  generally indicates that a model has substantial support while a suite of best models  
216 with low weights ( $w \sim 0$ ) indicates that no single variable plays a substantial role in mediating  
217 infection dynamics [47]. Using the *Anova* function in the R package car [48], we assessed  
218 significance of the effects using Wald  $\chi^2$  statistics for the winning model.

219 **Supplementary Table 1.** Model selection for prevalence of *M. ozzardi* across demographic  
220 variables. Variables include age, sex, education, ethnicity, and location. Global = focal model,  
221 m8 = winning model.

## 222 Protocol and data availability

223 All pipelines for statistical analysis and data visualization are available at  
224 <https://github.com/zamanianlab/Mansonella-ms>.

225  
226 Raw read data used for assembly of mitogenomes of *M. ozzardi* isolates Moz-Col-195, Moz-  
227 Col-204, Moz-Col-220 and Moz-Col-239 are submitted under NCBI BioProject XYZ. The  
228 accession numbers of the assembled mitogenomes are XYZ, XYZ, XYZ, XYZ respectively. The  
229 mitogenomes of isolates Moz-Brazil-1 and Moz-Venz-1 were assembled from previously  
230 reported raw read datasets [16] available from NCBI BioProject PRJNA917722 and  
231 PRJNA917766 respectively. The corresponding GenBank accessions for these mitogenomes  
232 are XYZ for Moz-Brazil-1 and XYZ for Moz-Venz-1.

## 233 Results

### 234 Parasite Prevalence

235 To assess *Mansonella* prevalence within our study population, we deployed a species-specific  
236 loop-mediated isothermal amplification (LAMP) assay [30] and compared diagnostic results with  
237 microscopic examination of thin blood smears. Across the first survey (samples 1-117), blood  
238 LAMP results show a higher prevalence of *M. ozzardi* infections ( 54/115, 46.9%) than single  
239 thin smear microscopy (16/104, 15.3%) and LAMP carried out using DNA from matched plasma  
240 (31/115, 26.9%) (**Figure 2 A**). Consensus blood LAMP results were derived from experiments  
241 involving DNA extractions from independent aliquots of blood as well as replicates of LAMP  
242 assays carried out in two laboratories using DNA from a single extraction (**Supplementary**  
243 **Figure 1 A**).

244  
245 Treating the blood LAMP as the truth case, thin smear microscopy shows a 31% sensitivity and  
246 plasma LAMP shows a 50% sensitivity. For the 30 samples where blood LAMP was positive  
247 and microscopy was negative, lower time (Tt) which is indicative of more parasite material being  
248 present in semi-quantitative LAMP (sq-LAMP) were observed (**Supplementary Figure 1 B-C**).  
249 We therefore hypothesized that the discrepancy between LAMP results and microscopy is likely  
250 associated with lower titers of microfilariae in venous blood leading to thin smear false negatives  
251 [49] or occult (amicrofilaremic) infections [21] that can only be detected using molecular  
252 methods. In both cases, we would expect the blood LAMP assay to display better sensitivity.  
253

254 Subsequent surveys (samples 118-186; samples 187-244) were used to probe potential  
255 associations between microfilaremia and *Mansonella* diagnostic results by incorporating  
256 quantitative microscopy. Blood LAMP assays showed an *M. ozzardi* prevalence of 33%  
257 (40/120). Among the 14 samples which tested positive in microscopy, 13 also tested positive in  
258 LAMP. Plasma LAMP (16%) and thin smear microscopy detected a lower prevalence (12%),  
259 reflecting the pattern observed in the first survey (**Figure 2 B**). Quantitative microscopy detected  
260 mf in 23/122 samples (19%), ranging from 0-11 mf/blood spot (**Figure 2 C**). Samples with the  
261 highest mf titers were most likely to be positive across blood and plasma LAMP assays and thin  
262 smears, while samples with lower mf titers were more likely to be negative in blood smears and  
263 only detected in the blood LAMP assay (**Figure 2 D**). This lends support to the hypothesis that  
264 low mf titers is a driver of false negatives in both thin smears and plasma LAMP assays.  
265

266 To explore whether occult infections could also be a factor contributing to the positive blood  
267 LAMP samples which had negative microscopy results, we re-sampled blood from six  
268 individuals that fit this pattern. A larger volume of blood (1 mL) was filtered to identify mf that  
269 could be circulating at titers not routinely detectable via thick and thin smear microscopy. All six  
270 samples were still microscopy negative, supporting the likelihood of occult infections. Whole  
271 blood LAMP was the most sensitive diagnostic test and identified a prevalence of 40% for *M.*  
272 *ozzardi* across all three surveys (**Table 1**).

273  
274

275

## 276 **Figure 2**

277 **A)** Diagnostic results derived from survey one blood samples (1-117) for in-field microscopy  
278 smears (M), LAMP using DNA extracted from blood ( $L_b$ ), and LAMP using matched DNA  
279 extracted from plasma ( $L_p$ ). **B)** Diagnostic results derived from surveys two and three (samples  
280 118-244) for in-field microscopy smears (M), LAMP using DNA extracted from blood ( $L_b$ ), and  
281 LAMP using matched DNA extracted from plasma ( $L_p$ ). **C)** Quantitative microscopy counts (qM)  
282 derived from surveys two and three blood samples (118-244). **D)** Quantitative microscopy  
283 counts of microfilariae stratified by  $L_b$  and  $L_p$  results and coloured by microscopy smear results.  
284 ( NN = negative  $L_b$  and negative  $L_p$ , IN= inconclusive  $L_b$  and negative  $L_p$ , PN = positive  $L_b$  and  
285 negative  $L_p$ , PP = positive  $L_b$  and positive  $L_p$ , NP = negative  $L_b$  and positive  $L_p$ ). Grey = negative  
286 for *M. ozzardi*; White = no result (A-C). LAMP assay data are specific to *M. ozzardi*.

287

## 288 **Supplementary Figure 1**

289 **A)** Diagnostic results derived from survey one blood samples (1-117) for four replicates of  
290 LAMP using DNA extracted from blood samples ( $L_b$ ) across two laboratories. Grey = negative  
291 for *M. ozzardi*. White = no result. **B)** Diagnostic results derived from survey one blood samples  
292 (1-117) for semi-quantitative LAMP (Tt). ND = not detected **C)** Semi-quantitative LAMP Tt  
293 counts (minutes) stratified by  $L_b$  and  $L_p$  results and colored by thin smear results. Dashed lines  
294 indicate Tt cutoffs ( $> 1$ ,  $< 30$  minutes = positive sq\_LAMP). (NN = negative  $L_b$  and negative  $L_p$ ,  
295 PN = positive  $L_b$  and negative  $L_p$ , PP = positive  $L_b$  and positive  $L_p$ , NP = negative  $L_b$  and positive  
296  $L_p$ ). LAMP assay data are specific to *M. ozzardi*.

297

298 **Table 1.** Summary and comparison of *M. ozzardi* diagnostic results for the entire study  
299 population.

## 300 **Population Demographics**

301 The three surveys consisted of individuals who reside in thirteen different communities situated  
302 between  $-02^{\circ}50'14.9496''$  north latitude and  $-03^{\circ}52'39.1980''$  south latitude; and -  
303  $069^{\circ}44'10.7880''$  and  $-070^{\circ}35'52.2240''$  west longitude (Figure3 A). A majority of our sampled  
304 population were centered in Puerto Nariño ( $n = 136$ ) (Table 2), where the prevalence of *M.*  
305 *ozzardi* as determined by blood LAMP is 44%. The next largest sampled communities in our  
306 survey, 12 de Octubre (24%;  $n = 25$ ) and San Pedro de Tipisca (14%;  $n = 21$ ), had lower  
307 prevalence. There was a higher prevalence of *M. ozzardi* mf identified via blood LAMP in males  
308 (49%;  $n = 84$ ; mean age = 40.1 years) compared to females (32%;  $n = 148$ ; mean age = 34.7  
309 years). The mean age of *M. ozzardi* positive individuals was higher than the mean age of  
310 negative individuals in females (Wilcox:  $p = 0.026$ ) but not males (Wilcox:  $p = 0.07$ ) (Figure 3 B).  
311 To further examine differences between infection prevalence across demographic variables, we  
312 assessed significance of the fixed effects using Wald  $\chi^2$  statistics and identified education and  
313 place of residence as drivers of prevalence (education binomial GLM:  $\chi^2 = 16.2647$ ,  $p =$   
314  $0.01240$ , case origin GLM:  $\chi^2 = 13.6850$ ,  $p = 0.03336$ ). However, given the limitation of the  
315 data we were unable to confirm significant differences within these groups due to unequal and  
316 small sample sizes amongst subsets.

317



318 Clinical histories were collected and additional serological tests were carried out for survey two  
319 and three samples (n = 117) (**Figure 3 C**) and compared across *M. ozzardi* blood LAMP  
320 positive and negative individuals (**Figure 3 D**). Symptoms and serology results that were  
321 differentially reported (abdominal pain, fever, joint pain, muscle pain, Hepatitis B antibodies, and  
322 Hepatitis C antibodies) between blood LAMP positive and negative individuals were examined  
323 further to determine if fixed effects or *M. ozzardi* infections were more likely to explain these  
324 data. We assessed significance of the fixed effects and blood LAMP results using Wald  $\chi^2$   
325 statistics and determined that *M. ozzardi* infection status did not significantly correlate to  
326 reported symptoms or serology results. Fixed effects including sex and age were identified as  
327 potential drivers of some of the reported symptoms and serology results but unequal and small  
328 sample sizes amongst subsets of data limited our post-hoc analysis.

329

### 330 **Figure 3**

331 **A)** A map of the study region in the Amazonas Department of Colombia depicting the  
332 community where individual participants reside. Point size reflects the number of samples  
333 collected and color represents the prevalence of *M. ozzardi* infection for each community. **B)** *M.*  
334 *ozzardi* prevalence as determined by blood LAMP assay stratified by sex and age (95% CI)  
335 (left) and histogram of *M. ozzardi* prevalence distribution by age (right). F = female, M = male **C)**  
336 *M. ozzardi* infection status and reported symptoms and serological test results for survey two  
337 and three individuals (n = 120). Orange = positive, present; Grey = negative, not-present; white  
338 indicates missing data. **D)** Donut plots reflecting relative fractions of *M. ozzardi* L<sub>b</sub> positive and  
339 L<sub>b</sub> negative individuals who self-reported symptoms and lab confirmed serological test results.

340

341 **Table 2.** Summary of Demographic and diagnostic data. Data includes a subset of the total  
342 study population where all summarized demographic information was provided on the  
343 questionnaire. (Age in years).

## 344 **Genomic Analysis**

345 Whole genome sequencing was performed on 4 samples (ID numbers 195, 204, 220 and 239)  
346 which tested positive in the *M. ozzardi* specific blood LAMP assay. Only sample 239 had  
347 detectable microfilariae in the quantitative microscopy assay. While a mapping analysis of the  
348 sequencing data showed that over 94% of the reads were from the human host, 1 to 6 % of  
349 reads mapped to the reference *M. ozzardi* genome assembly and to the *Wolbachia* wMoz  
350 genome assembly, although at a low coverage (**Supplementary Figure 2**).

351

352 Sufficient read coverage was obtained for successful assembly of complete, circular  
353 mitogenomes for each isolate. The assembled mitogenomes displayed more than 99.6%  
354 sequence identity to each other and to previously reported *M. ozzardi* mitogenomes from Brazil  
355 [21,33], as well as to the newly assembled mitogenomes from isolates Moz-Brazil-1 and Moz-  
356 Venz-1 obtained from Brazil and Venezuela respectively [16]. A phylogenetic analysis of all *M.*  
357 *ozzardi* mitogenomes in conjunction with *M. perstans* mitogenomes from Brazil [21] and  
358 Cameroon [38] showed a distinct *M. ozzardi* clade with very short branch lengths between  
359 various isolates and a clear separation from the *M. perstans* clade (**Figure 4**). Together, these  
360 results confirm the presence of *M. ozzardi* infection in these individuals.

361

362

### 363 **Figure 4**

364 Maximum-likelihood tree based on whole-mitogenome alignments of various *M. ozzardi* and *M.*  
365 *perstans* isolates. Abbreviation Moz and Mpe and indicate *M. ozzardi* and *M. perstans*  
366 respectively. The GenBank accessions are indicated in parenthesis next to isolate names,  
367 followed by the country of origin in the second parenthesis. Blue colors mark the isolates  
368 sequenced in this study. The DNA substitution model HKY+F+I was found to be the best fit  
369 according to Bayesian Information Criteria in ModelFinder. Values of ultrafast bootstrap support  
370 calculated with 1000 replicates is shown for branches with value higher than 80.

371

### 372 **Supplementary Figure 2**

373 **A)** Sequencing read coverage from different *M. ozzardi* isolates on the reference nuclear  
374 contigs from Moz-Venz-1 genome assembly. **B)** Sequencing read coverage from different *M.*  
375 *ozzardi* isolates on the *Wolbachia* wMoz reference genome assembly.

## 376 **Cryopreservation of Blood-Dwelling Parasite Stage**

377 As a first step towards establishing the lifecycle of *M. ozzardi* in a laboratory environment, we  
378 sought to functionally cryopreserve microfilariae and observe viable and active worms after  
379 thawing samples. We collected peripheral blood from individuals who were positive for *M.*  
380 *ozzardi* via blood LAMP assay and thin smear microscopy in our initial survey. Blood samples  
381 were mixed with dimethyl sulfoxide (DMSO) and kept at -80°C. We observed revitalization of  
382 microfilariae upon thawing at 37°C, whereby motility increased over the first 24 hour incubation  
383 period before steadily declining (**Figure 5 A**). Videos showed viable and healthy microfilariae  
384 (**Figure 5 B**) that may allow for membrane feeding of lab colonies of *Culicoides* and the  
385 production of infective-stage larvae (L3) in a laboratory setting.

386

### 387 **Figure 5**

388 **A)** Motility of cryo-preserved *M. ozzardi* microfilariae over 48 hours as measured by an optical  
389 flow algorithm. **B)** Brightfield images and optical flowmaps of videos used for motility analysis of  
390 thawed cryopreserved *Mansonella* samples aligned with the timepoints in (A). Brighter regions  
391 of the flowmaps reflect areas where more parasite movement was detected.

## 392 **Discussion**

393 We conducted three seroprevalence surveys to better map the distribution of *Mansonella*  
394 infections among indigenous communities in the Amazon basin of Colombia. Blood smear  
395 microscopy identified microfilariae in 12.7% of sampled individuals, which falls within the range  
396 of historical studies in the region [23,24,50]. Blood LAMP assays detected *M. ozzardi* DNA in  
397 40% of sampled individuals, in closer agreement with more recent PCR-based surveys in the  
398 Amazon region of neighboring countries [26,28,51,52]. Our survey data adds to the growing  
399 body of evidence that microscopy-based approaches can drastically underestimate the true  
400 prevalence of global mansonellosis [5,14,26–30,51–53].

401  
402 Molecular diagnostic assays can be leveraged to capture a broader range of infection states,  
403 including low microfilaremiias or afilememic (occult) infections [21]. The recovery of complete  
404 mitogenomes confirms the presence of *M. ozzardi* DNA in blood samples that previous  
405 microscopy diagnostics could not detect, providing further confidence in LAMP diagnostic  
406 results. The distribution of *M. ozzardi* adults within the human body is not fully resolved [54], but  
407 it is presumed that they commonly take residence in subcutaneous tissues and possibly the  
408 serous cavities. These larger stages are the likely source of blood-detectable nucleic acids in  
409 molecular diagnostic assays. LAMP assays provide a sensitive, specific, and potentially cost-  
410 effective approach for the surveillance of filarial nematode infections in human and vector  
411 populations [30,55–57]. The development of direct LAMP assays [58] not reliant on DNA  
412 extraction will add to the convenience of this approach in endemic settings.

413  
414 The establishment of a cryopreservation protocol can facilitate the eventual rearing of *M.*  
415 *ozzardi* in laboratory settings, including controlled blood-feeding of reanimated microfilariae to  
416 susceptible colonies of biting midges. In vitro phenotyping of *Mansonella* drug responses [59]  
417 can help resolve the genetic and molecular basis for observed differences in antifilarial drug  
418 susceptibility across species [9,10,12,13,15,60] and open avenues for the screening and  
419 discovery of new therapeutic leads for mansonellosis.

420  
421 *Mansonella* is neglected even among neglected pathogens due to a lack of investment in  
422 studying its biology and potential health impacts [4,8,61]. More complete demographic and  
423 clinical data are needed to determine *M. ozzardi* pathogenicity and assess risk factors. Adult  
424 worms disperse somewhat randomly into various tissues and body cavities, the consequences  
425 of which can vary considerably across individuals but have historically been summarized as  
426 relatively non-pathogenic. Although there are growing clinical case reports suggesting  
427 appreciable pathogenicity [4], it is difficult to streamline causal associations with more subtle  
428 health impacts. The current established threshold for addressing human filariasis is a causal  
429 association with significant morbidity, including blindness and physical disfigurement.  
430 Investigation of subclinical or secondary impacts of infection would shift the threshold of  
431 potential human clinical concern in mansonellosis-endemic regions to the same threshold that  
432 often triggers action as it relates to subclinical nematode infections of livestock and companion  
433 animals. We expect that improved diagnostic tools, growing genomic resources, and methods to  
434 study *Mansonella* in laboratory settings will facilitate this goal.

## 435 Acknowledgements

436 The authors thank the communities, the Secretaria de Salud Departamental del Amazonas,  
437 Alcaldia de Puerto Nariño, E.S.E Hospital San Rafael de Puerto Nariño, and the Laboratorio  
438 Departamental de Salud Pública de Leticia for their contributions to this study. We sincerely  
439 thank Julian Rodriguez and Corporacion Corpotropica for their assistance and coordination of  
440 activities at the study sites. In addition, we would like to thank the staff of One Health lab and  
441 auxiliary personnel at all the study sites for their assistance. Thanks to the Abbott Pandemic  
442 Defense Coalition for the provision of laboratory testing kits.

## 443 Funding

444 KJD was supported by a UW-SciMed GRS Fellowship (scimedgrs.wisc.edu) and NIH  
445 Parasitology and Vector Biology Training grant number T32 AI007414 (NIH.gov). This work was  
446 supported by a seed grant from the University of Wisconsin-Madison Global Health Institute  
447 (GHI) to MZ. CKSC, ZL, AS and SR gratefully acknowledge funding and support from New  
448 England Biolabs.

## 449 Conflicts

450 CKSC, ZL, AS and SR are employed by New England Biolabs, a manufacturer and vendor of  
451 molecular biology reagents. This affiliation does not affect the authors' impartiality, adherence to  
452 journal standards and policies or availability of data. All other authors report no potential  
453 conflicts of interest.

## 454 References

- 455 1. Schluth CG, Standley CJ, Bansal S, Carlson CJ. Spatial parasitology and the unmapped  
456 human helminthiasis. *Parasitology*. **2023**; :1–9.
- 457 2. B elard S, Gehringer C. High Prevalence of Mansonella Species and Parasitic Coinfections  
458 in Gabon Calls for an End to the Neglect of Mansonella Research. *J Infect Dis*. **2021**;  
459 223(2):187–188.
- 460 3. Mourembou G, Fenollar F, Lekana-Douki JB, et al. Mansonella, including a Potential New  
461 Species, as Common Parasites in Children in Gabon. *PLoS Negl Trop Dis*. **2015**;  
462 9(10):e0004155.
- 463 4. Ta-Tang T-H, Crainey JL, Post RJ, Luz SL, Rubio JM. Mansonellosis: current perspectives.  
464 *Res Rep Trop Med*. **2018**; 9:9–24.
- 465 5. Sandri TL, Kreidenweiss A, Cavallo S, et al. Molecular Epidemiology of Mansonella  
466 Species in Gabon. *J Infect Dis*. **2021**; 223(2):287–296.
- 467 6. Stensgaard A-S, Vounatsou P, Onapa AW, et al. Ecological Drivers of Mansonella perstans  
468 Infection in Uganda and Patterns of Co-endemicity with Lymphatic Filariasis and Malaria.  
469 *PLoS Negl Trop Dis*. **2016**; 10(1):e0004319.
- 470 7. Phillips RO, Frimpong M, Sarfo FS, et al. Infection with Mansonella perstans Nematodes in  
471 Buruli Ulcer Patients, Ghana. *Emerg Infect Dis*. **2014**; 20(6):1000–1003.
- 472 8. Ritter M, Ndongmo WPC, Njouendou AJ, et al. Mansonella perstans microfilaremic  
473 individuals are characterized by enhanced type 2 helper T and regulatory T and B cell  
474 subsets and dampened systemic innate and adaptive immune responses. *PLoS Negl Trop*  
475 *Dis*. **2018**; 12(1):e0006184.
- 476 9. Bregani ER, Rovellini A, Mba idoum N, Magnini MG. Comparison of different anthelmintic  
477 drug regimens against Mansonella perstans filariasis. *Trans R Soc Trop Med Hyg*. **2006**;  
478 100(5):458–463.

- 479 10. Van Hoegaerden M, Ivanoff B, Flocard F, Salle A, Chabaud B. The use of mebendazole in  
480 the treatment of filariases due to *Loa loa* and *Mansonella perstans*. *Ann Trop Med*  
481 *Parasitol.* **1987**; 81(3):275–282.
- 482 11. Simonsen PE, Onapa AW, Asio SM. *Mansonella perstans* filariasis in Africa. *Acta Trop.*  
483 **2011**; 120 Suppl 1:S109–20.
- 484 12. Gonzalez AA, Chadee DD, Rawlins SC. Ivermectin treatment of mansonellosis in Trinidad.  
485 *West Indian Med J.* **1999**; 48(4):231–234.
- 486 13. Simonsen PE, Fischer PU, Hoerauf A, Weil G. Manson's Tropical Diseases, 23rd Edition:  
487 The Filariases. *Manson's Tropical Diseases.* unknown; 2014. p. 737–765.
- 488 14. Ta-Tang T-H, Luz SLB, Merino FJ, et al. Atypical *Mansonella ozzardi* *Microfilariae* from an  
489 Endemic Area of Brazilian Amazonia. *Am J Trop Med Hyg.* **2016**; 95(3):629–632.
- 490 15. Coulibaly YI, Dembele B, Diallo AA, et al. A randomized trial of doxycycline for *Mansonella*  
491 *perstans* infection. *N Engl J Med.* **2009**; 361(15):1448–1458.
- 492 16. Sinha A, Li Z, Poole CB, et al. Genomes of the human filarial parasites *Mansonella*  
493 *perstans* and *Mansonella ozzardi*. *Frontiers in Tropical Diseases* [Internet]. 2023 [cited  
494 2023 Apr 3]; 4. Available from: <https://doi.org/10.3389/fitd.2023.1139343>
- 495 17. Mathison BA, Couturier MR, Pritt BS. Diagnostic Identification and Differentiation of  
496 *Microfilariae*. *J Clin Microbiol* [Internet]. **2019**; 57(10). Available from:  
497 <http://dx.doi.org/10.1128/JCM.00706-19>
- 498 18. Crainey JL, Bessa Luz SL. Light Microscopic Detection of *Mansonella ozzardi*  
499 *Parasitemias*. *Clin. Infect. Dis.* 2019. p. 2156.
- 500 19. Coulibaly YI, Soumaoro L, Dembele B, Hodges M, Zhang Y. POTENTIAL CROSS  
501 REACTIVITY OF MANSONELLA PERSTANS WITH WUCHERERIA BANCROFTI BY  
502 FILARIASIS TEST STRIPS. *AMERICAN JOURNAL OF TROPICAL MEDICINE AND*  
503 *HYGIENE. AMER SOC TROP MED & HYGIENE 8000 WESTPARK DR, STE 130,*  
504 *MCLEAN, VA 22101 USA; 2019. p. 160–160.*
- 505 20. Wanji S, Amvongo-Adjia N, Koudou B, et al. Cross-Reactivity of Filariasis ICT Cards in  
506 Areas of Contrasting Endemicity of *Loa loa* and *Mansonella perstans* in Cameroon:  
507 Implications for Shrinking of the Lymphatic Filariasis Map in the Central African Region.  
508 *PLoS Negl Trop Dis.* **2015**; 9(11):e0004184.
- 509 21. Crainey JL, Costa CHA, Oliveira Leles LF de, et al. Deep Sequencing Reveals Occult  
510 *Mansonellosis* Coinfections in Residents From the Brazilian Amazon Village of São Gabriel  
511 da Cachoeira. *Clin Infect Dis.* **2020**; 71(8):1990–1993.
- 512 22. Kozek WJ, Palma G, Valencia W, Montalvo C, Spain J. Filariasis in Colombia: prevalence  
513 of *Mansonella ozzardi* in the Departamento de Meta, Intendencia del Casanare, and  
514 Comisaría del Vichada. *Am J Trop Med Hyg.* **1984**; 33(1):70–72.
- 515 23. Lightner LK, Ewert A, Corredor A, Sabogal E. A parasitologic survey for *Mansonella ozzardi*  
516 in the Comisaría del Vaupés, Colombia. *Am J Trop Med Hyg.* **1980**; 29(1):42–45.
- 517 24. Kozek WJ, D'Alessandro A, Silva J, Navarette SN. Filariasis in Colombia: prevalence of


- 518           mansonellosis in the teenage and adult population of the Colombian bank of the Amazon,  
519           Comisaria del Amazonas. *Am J Trop Med Hyg.* **1982**; 31(6):1131–1136.
- 520   25. Tidwell MA, Tidwell MA. Development of *Mansonella ozzardi* in *Simulium amazonicum*, *S.*  
521           *argentiscutum*, and *Culicoides insinuatus* from Amazonas, Colombia. *Am J Trop Med Hyg.*  
522           *American Society of Tropical Medicine and Hygiene*; **1982**; 31(6):1137–1141.
- 523   26. Calvopina M, Chiluisa-Guacho C, Toapanta A, Fonseca D, Villacres I. High Prevalence of  
524           *Mansonella ozzardi* Infection in the Amazon Region, Ecuador. *Emerg Infect Dis.* **2019**;  
525           25(11):2081–2083.
- 526   27. Jiménez M, González LM, Carranza C, et al. Detection and discrimination of *Loa loa*,  
527           *Mansonella perstans* and *Wuchereria bancrofti* by PCR-RFLP and nested-PCR of  
528           ribosomal DNA ITS1 region. *Exp Parasitol.* **2011**; 127(1):282–286.
- 529   28. Tang T-HT, López-Vélez R, Lanza M, Shelley AJ, Rubio JM, Luz SLB. Nested PCR to  
530           detect and distinguish the sympatric filarial species *Onchocerca volvulus*, *Mansonella*  
531           *ozzardi* and *Mansonella perstans* in the Amazon Region. *Mem Inst Oswaldo Cruz.* **2010**;  
532           105(6):823–828.
- 533   29. Fischer P, Büttner DW, Bamuhiiga J, Williams SA. Detection of the filarial parasite  
534           *Mansonella streptocerca* in skin biopsies by a nested polymerase chain reaction-based  
535           assay. *Am J Trop Med Hyg.* **1998**; 58(6):816–820.
- 536   30. Poole CB, Sinha A, Ettwiller L, et al. In Silico Identification of Novel Biomarkers and  
537           Development of New Rapid Diagnostic Tests for the Filarial Parasites *Mansonella perstans*  
538           and *Mansonella ozzardi*. *Sci Rep.* **2019**; 9(1):10275.
- 539   31. Zinser EW, McTier TL, Kernell NS, Woods DJ. Cryogenic preservation of *Dirofilaria immitis*  
540           microfilariae, reactivation and completion of the life-cycle in the mosquito and vertebrate  
541           hosts. *Parasit Vectors.* **2021**; 14(1):367.
- 542   32. Wheeler NJ, Gallo KJ, Rehborg EJG, Ryan KT, Chan JD, Zamanian M. wrmXpress: A  
543           modular package for high-throughput image analysis of parasitic and free-living worms.  
544           *PLoS Negl Trop Dis.* **2022**; 16(11):e0010937.
- 545   33. Crainey JL, Marín MA, Silva TRR da, et al. *Mansonella ozzardi* mitogenome and  
546           pseudogene characterisation provides new perspectives on filarial parasite systematics and  
547           CO-1 barcoding. *Sci Rep.* **2018**; 8(1):6158.
- 548   34. Sinha A, Li Z, Poole CB, et al. Multiple lineages of nematode-*Wolbachia* symbiosis in  
549           supergroup F and convergent loss of bacterioferritin in filarial *Wolbachia*. *Genome Biology*  
550           and Evolution. 2023; :evad073. Available from: <https://doi.org/10.1093/gbe/evad073>
- 551   35. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods.* **2012**;  
552           9(4):357–359.
- 553   36. Danecek P, Bonfield JK, Liddle J, et al. Twelve years of SAMtools and BCFtools.  
554           *Gigascience* [Internet]. **2021**; 10(2). Available from:  
555           <http://dx.doi.org/10.1093/gigascience/giab008>
- 556   37. Jin J-J, Yu W-B, Yang J-B, et al. GetOrganelle: a fast and versatile toolkit for accurate de

- 557 novo assembly of organelle genomes. *Genome Biol.* **2020**; 21(1):241.
- 558 38. Chung M, Aluvathingal J, Bromley RE, et al. Complete Mitochondrial Genome Sequence of  
559 *Mansonella perstans*. *Microbiol Resour Announc* [Internet]. **2020**; 9(30). Available from:  
560 <http://dx.doi.org/10.1128/MRA.00490-20>
- 561 39. Yoon S-H, Ha S-M, Lim J, Kwon S, Chun J. A large-scale evaluation of algorithms to  
562 calculate average nucleotide identity. *Antonie Van Leeuwenhoek.* **2017**; 110(10):1281–  
563 1286.
- 564 40. Nakamura T, Yamada KD, Tomii K, Katoh K. Parallelization of MAFFT for large-scale  
565 multiple sequence alignments. *Bioinformatics.* **2018**; 34(14):2490–2492.
- 566 41. Trifinopoulos J, Nguyen L-T, Haeseler A von, Minh BQ. W-IQ-TREE: a fast online  
567 phylogenetic tool for maximum likelihood analysis. *Nucleic Acids Res.* **2016**;  
568 44(W1):W232–5.
- 569 42. Kalyaanamoorthy S, Minh BQ, Wong TKF, Haeseler A von, Jeremiin LS. ModelFinder: fast  
570 model selection for accurate phylogenetic estimates. *Nat Methods.* **2017**; 14(6):587–589.
- 571 43. Hoang DT, Chernomor O, Haeseler A von, Minh BQ, Vinh LS. UFBoot2: Improving the  
572 Ultrafast Bootstrap Approximation. *Mol Biol Evol.* **2018**; 35(2):518–522.
- 573 44. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree  
574 display and annotation. *Nucleic Acids Res.* **2021**; 49(W1):W293–W296.
- 575 45. Crawley MJ. *The R Book*. John Wiley & Sons; 2012.
- 576 46. Mazerolle MJ. AICcmodavg: Model selection and multimodel inference based on (Q)AIC(c)  
577 [Internet]. 2023. Available from: <https://cran.r-project.org/package=AICcmodavg>
- 578 47. Burnham KP, Anderson DR. *Model Selection and Inference: A Practical Information-*  
579 *Theoretic Approach*. Springer New York; 1998.
- 580 48. Fox J, Weisberg S. *An R Companion to Applied Regression*. SAGE Publications; 2018.
- 581 49. Mischlinger J, Manego RZ, Mombo-Ngoma G, et al. Diagnostic performance of capillary  
582 and venous blood samples in the detection of *Loa loa* and *Mansonella perstans*  
583 microfilaraemia using light microscopy. *PLoS Negl Trop Dis.* **2021**; 15(8):e0009623.
- 584 50. Shelley AJ. A preliminary survey of the prevalence of *Mansonella ozzardi* in some rural  
585 communities on the river Purus, state of Amazonas, Brazil. *Ann Trop Med Parasitol.* **1975**;  
586 69(3):407–412.
- 587 51. Abraham CMM, Py-Daniel V, Luz SLB, Fraiji NA, Stefani MMA. Detection of *Mansonella*  
588 *ozzardi* among blood donors from highly endemic interior cities of Amazonas state,  
589 northern Brazil. *Transfusion.* **2019**; 59(3):1044–1051.
- 590 52. Medeiros JF, Almeida TAP, Silva LBT, et al. A field trial of a PCR-based *Mansonella*  
591 *ozzardi* diagnosis assay detects high-levels of submicroscopic *M. ozzardi* infections in both  
592 venous blood samples and FTA card dried blood spots. *Parasit Vectors.* **2015**; 8:280.
- 593 53. Medeiros JF, Fontes G, Nascimento VL do, et al. Sensitivity of diagnostic methods for


- 594 Mansonella ozzardi microfilariae detection in the Brazilian Amazon Region. Mem Inst  
595 Oswaldo Cruz. **2018**; 113(3):173–177.
- 596 54. Lima NF, Veggiani Aybar CA, Dantur Juri MJ, Ferreira MU. Mansonella ozzardi: a  
597 neglected New World filarial nematode. Pathog Glob Health. **2016**; 110(3):97–107.
- 598 55. Amambo GN, Innocentia N, Abong RA, et al. Application of loop mediated isothermal  
599 amplification (LAMP) assays for the detection of Onchocerca volvulus, Loa loa and  
600 Mansonella perstans in humans and vectors. Frontiers in Tropical Diseases [Internet].  
601 **2023**; 3. Available from: <https://www.frontiersin.org/articles/10.3389/fitd.2022.1016176>
- 602 56. Ta-Tang T-H, Berzosa P, Rubio JM, et al. Evaluation of LAMP for the diagnosis of Loa loa  
603 infection in dried blood spots compared to PCR-based assays and microscopy. Mem Inst  
604 Oswaldo Cruz. **2022**; 116:e210210.
- 605 57. Poole CB, Li Z, Alhassan A, et al. Colorimetric tests for diagnosis of filarial infection and  
606 vector surveillance using non-instrumented nucleic acid loop-mediated isothermal  
607 amplification (NINA-LAMP). PLoS One. **2017**; 12(2):e0169011.
- 608 58. Avendaño C, Patarroyo MA. Loop-Mediated Isothermal Amplification as Point-of-Care  
609 Diagnosis for Neglected Parasitic Infections. Int J Mol Sci [Internet]. **2020**; 21(21). Available  
610 from: <http://dx.doi.org/10.3390/ijms21217981>
- 611 59. Njouendou AJ, Kien CA, Esum ME, et al. In vitro maintenance of Mansonella perstans  
612 microfilariae and its relevance for drug screening. Exp Parasitol. **2019**; 206:107769.
- 613 60. Fischer P, Tukesiga E, Büttner DW. Long-term suppression of Mansonella streptocerca  
614 microfilariae after treatment with ivermectin. J Infect Dis. **1999**; 180(4):1403–1405.
- 615 61. Metenou S, Babu S, Nutman TB. Impact of filarial infections on coincident intracellular  
616 pathogens: Mycobacterium tuberculosis and Plasmodium falciparum. Curr Opin HIV AIDS.  
617 **2012**; 7(3):231–238.







A



B



**A****B****C****D**

Count

9

6

3




0

Thin Smear


● Negative



● Not tested

● Positive



Tree scale: 0.1





	Microscopy Smear / LAMP-Plasma Positive	Microscopy Smear / LAMP-Plasma Negative	No Result	Total
LAMP-Blood Positive	27 / 42	57 / 52	10 / 0	94
LAMP-Blood Negative	3 / 8	129 / 132	9 / 1	141
	30 / 50	186 / 184	19 / 1	235

	Young Adult 18 - 32	Adult 33 - 54	Mature Adult 55 - 89	Total				
Age	101	104	29	234				
Sex (Female / Male)	69 / 32	68 / 36	12 / 17	149 / 85				
<i>M. ozzardi</i> (L <sub>b</sub> / L <sub>p</sub> / Microscopy)	31 / 16 / 9	42 / 24 / 16	20 / 10 / 5	93 / 50 / 30				
	Primary	High School	Technical	University	Other	Not Reported		
Education	59	81	52	16	2	24		
	Bora	Cocama	Senu	Ticuna	Tokami	Multiethnic	Not Reported	
Ethnicity	1	5	1	151	1	3	72	
	Lomas Lindas	12 De Octubre	San Francisco	Villa Andrea	Puerto Narino	San Pedro De Tipisca	Other	Not Reported
Location	11	25	9	15	136	21	14	3